Sequenom Preparing Response to FDA on Warning Letter

Sequenom said in an SEC document that its SensiGene test, which the company believes was cited by the FDA for being improperly marketed without FDA approval, is an LDT and meant "solely for use within our CLIA-certified and CAP-accredited laboratory."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories